Six- and seven-figure prices plus complicated administration and patient monitoring add up to difficult product launches for cell and gene therapies. Big pharma companies with novel medicines for hemophilia, cancer and other diseases are facing real-world challenges related to the cost and complexity of these products, which has made for slow initial uptake and measured sales growth.
Big Pharma Faces Cell And Gene Therapy Market Realities
Real-World Challenges For Novel Products
Big pharma executives at ARM’s Cell and Gene Meeting on the Mesa shared some of the practical challenges of bringing one-time treatments to market in hemophilia, cancer and beyond.
More from Gene Therapies
More from Business
• By
Private Company Edition: The latest group of drug developers to announce venture capital financings is remarkable for its geographic diversity, from Character Biosciences’ $93m series B round in the US to Augustine’s $85m series B in Belgium to a $29.2m series C for Aculys in Japan.
• By
The head of the Spanish medical dermatology specialist told Scrip that maintaining the status quo will only result in the continent’s life sciences sector slipping further behind the US and China.
• By
Stakeholders are pleading for newly confirmed FDA Commissioner Martin Makary to stand up for the agency's high scientific standards and staff as he begins his term.